Introduction. Skin toxicity in patients receiving novel therapeutic cancer agents has become a very important marker in determining drug activity, but it can also severely impact their quality of life. About half of the patients receiving this type of oncologic treatment will develop cutaneous reactions, that is why adequate understanding and management of these side effects is very important for drug adherence and patients' quality of life.
INTRODUCTION
The advent of new therapeutic agents and strategies in the field of oncology, most notably the development of personalized medicine, has resulted in a prolonged life and longer disease free survival for cancer patients. However, this new era of oncological medicine brought with it cutaneous reactions that arise as side effects from these therapies.
Skin conditions can result in a reduction or discontinuation of chemotherapy regimens and can have a severe impact on cancer patients' quality of life, with very important physical, psychological and financial implications [1] .
Skin toxicity that is usually induced by classical chemotherapy can present as nail changes (paronychia, changes in pigmentation, onycholysis, mees lines), exfoliative dermatitis, hyperpigmentation, hand-foot syndrome (acral erythema, palmoplantar erythrodysesthesia), alopecia, photosensitivity and severe skin reactions like Stevens Johnson syndrome, Raynaud syndrome or ulcers [2] .
Patients treated with novel targeted anticancer drugs, like epidermal growth factor receptor inhibitors (EGFRI) or mammalian target of rapamycin inhibitors or tyrosine kinase inhibitors can develop muco-cutaneous side effects such as acneiform-like rash, pruritus, paronychia, xerosis, exanthematous popular rash, hair changes, hand-foot syndrome, hypo/hyperpigmentation [2, 3] .
For the diagnosis and management of these side effects, a multidisciplinary team approach is necessary, usually consisting of a medical oncologist and a dermatology specialist. A clinical staging of these side effects can help orient the physician to either reduce doses or discontinue cancer therapy altogether, with an important impact on clinical outcome. There are several grading systems currently in use: the National Cancer Institute's Common Criteria for Adverse Events (CTCAE) -most frequently used scale in clinical practice, DERETTDermatologic Reaction Targeted Therapy -patient Symptom Experience Diary, the Functional Assessment of Cancer Therapy Epidermal Growth Factor Receptor Inhibitor 18 (FACT-EGFRI-18) scale, Skindex-16 and Hair Specific Skindex-29, the HandFoot Syndrome 14 (HFS-14), mTOR inhibitorassociated stomatitis scale (mIAS) [4] .
Using these tools to grade the cutaneous adverse reactions in cancer patients helps the physician to objectively measure their impact on patients quality of life and, subsequently, to manage the doses and to reassess the therapeutic protocol for these patients.
The aim of our study is to measure the impact of cutaneous side effects on patients' quality of life and to verify if skin toxicity can represent an early marker of tumour shrinkage and if this can be associated with clinical benefit.
MATERIALS AND METHODS

Study design
We conducted a prospective study of all oncologic patients presenting with dermatologic adverse events in a tertiary cancer center. Baseline evaluation consisted of a dermatologic consultation including type of adverse events (hand-foot syndrome, erythema, hypo/hyperpigmentation, acneiform rash, paronychia, xerosis, hair changes), severity (according to CTCAE v4.0 scale [5] ) and therapeutic intervention. All patients were asked to complete a validated quality of life questionnaire -DLQI (Dermatology Quality of Life Index), consisting of 10 simple questions that assess the patient's perception regarding the impact of skin pathology on their feelings, daily activities, work, personal relationships in the last week. This questionnaire was developed in 1994 by Finlay AY and Khan GK based on the answers of one hundred and twenty persons with different skin toxicities who were asked about the impact of their disease in their lives [6] . Each question is scored from 0 (not at all or not relevant) to 3 (very high impact on daily activities), with higher scores meaning a greater impact on patients' quality of life. This questionnaire is the most frequently used in dermatologic trials all over the world; it has been validated for use in over 90 different languages, including Romanian, and is readily available online from the Cardiff University Department of Dermatology [7] .
Clinical data regarding cancer type, staging and chemotherapy regimen as well as concomitant therapy for coexisting conditions was collected at baseline and reviewed at each subsequent study visit. Follow-up visits were scheduled every 3 months and all patients were followed for a minimum of 6 months after adverse event (AE) resolution or until death, whichever occurred first. Data regarding the evolution of the underlying disease and the impact of the dermatologic adverse event on the oncologic treatment was collected at each follow-up visit. Of note, none of the patients received prophylactic dermatologic treatment.
Outcome measures
The primary end-point of the study was the impact of chemotherapy on the quality of life (QOL) of oncologic patients, as assessed by the DLQI questionnaire. Disease progression at 6 months follow-up and the association between cutaneous AE severity and response to treatment were seconddary end points in the study.
Statistical analysis
Results are expressed as frequencies for categorical variables (further analyzed by Fisher's exact test), mean and standard deviation for normal continuous variables (analyzed by Student's t test), and median and extremes for non-normal continuous variables (analyzed by the Mann-Whitney U and Kruskall Wallis tests). DLQI levels were compared across study groups, acording to gender and disease severity using the Mann Whitney U test. Hypothesis testing was 2-tailed, with p < 0.05 considered statistically significant. The statistical software package SPSS for Windows Version 16.0 (SPSS Inc., Chicago, IL) was used to analyze the data.
RESULTS
Fifty-two patients (25 female, mean age 56 ± 11 years) presented with dermatologic adverse events (AE) to chemotherapy in our unit between October 2015 -October 2017. The majority of patients (32/52) were diagnosed with stage IV cancer and all others had advanced disease using TNM classification staging system. Most patients (13/52) were undergoing chemotherapy for head and neck cancers, followed by lung cancer (9/52) and colorectal cancer (7/52), with cetuximab (an EGFR inhibitor) being used in 18 cases (34%), followed by erlotinib (TK inhibitor) in 14 (27%) and conventional chemotherapy in 12 (23%) of cases. Baseline data is shown in detail in Table 1 . Papulopustular rash (acneiform rash) was the most frequently noted AE (60%), followed by hand foot syndrome (10%) and various other conditions (Table 2) . Twenty eight patients (53%) developed more than one type of cutaneous adverse reactions, in these cases the more severe toxicity was taken into consideration for further analysis. 36% of cases were graded as mild, 44% were graded as moderate and 20% were considered severe, according to Common Terminology Criteria for Adverse Events v4.0 score. Most patients (39/52 -75%) received topical treatment using corticosteroid and vitamin K1 cream [8] . Twelve patients (23.1%) required systemic therapy (antibiotics ± corticosteroids) and 1 patient received no additional dermatological treatment. Most patients presenting with mild AE (89.4%) did not delay or discontinue oncologic medication, while 20/33 (60.6%) patients presenting with moderate or severe AE had to discontinue treatment for 1 to 2 weeks (p < 0.001 Fisher's exact test).
Patients who developed either moderate or severe cutaneous AE were more likely to achieve complete or partial response to therapy at 3 months than those who only developed mild AE (48.5% vs. 15.7%, p = 0.035 Fisher's exact test). At 6 months follow-up, 12 out of 33 patients (36.3%) with moderate or severe AE still had complete or partial response to therapy compared to just 3/19 (15.7%) with mild cutaneous AE at baseline; however the difference was no longer statistically significant (p = 0.2 Fisher's exact test).
DLQI scores were associated with AE severity, with more severe disease resulting in lower QOL scores (Fig. 1) , with median DQLI of 2 (range 0-19), 5 (range 0-24) and 5.5 (range 2-24) for mild, moderate and severe manifestations respectively (p = 0.012, Kruskall-Wallis). Female patients showed more severe QOL impairment as a result of cutaneous AE, with significantly higher median DLQI compared to male patients at univariate analysis 5, range 0-24 vs. 2, range 0-13 p = 0.038 Mann Whitney U) (Fig. 2) .
There was no significant difference in the severity of cutaneous toxicity or QOL impairment according to the type of cancer treatment. Patients receiving targeted therapy had similar median DLQI scores compared with those on taxan-based conventional chemotherapy regimens (3, range 0-24 vs. 5, range 0-24, p = 0.11 Mann Whitney U) and a similar rate of moderate/severe adverse events (57.5% vs. 83.3%, p = 0.17 Fisher's exact test). 
DISCUSSION
Chemotherapy and EGFR inhibitor related skin toxicities in cancer patients are a relatively frequent occurrence, with an important impact on patient quality of life which can have significant implications from a therapeutic point of view. About 50% of newly diagnosed cancer patients will develop a treatable skin condition during or after their oncologic treatment [9] . A particularly interesting characteristic of these adverse reactions is the association between the severity of the skin toxicities and a favorable response to therapy. This paradox means that patients with the most severe manifestations, including grade III and IV CTCAE toxicity, requiring systemic therapy for their skin conditions, are likely to benefit the most from their oncologic regimen.
In our study we analyzed the impact of skin toxicity on patient's quality of life using a standard dedicated questionnaire -the DLQI. We found that moderate and severe adverse reactions have a significantly greater impact on patients' social lives than mild or moderate skin toxicities. Furthermore, these reactions appear to alter women's quality of life significantly more than men's QOL (p = 0.038). To our knowledge this is the first study suggesting that gender may play an important role in the perceived impact of cancer therapy-related skin toxicity on patients' quality of life.
A secondary end point was the association between the severity of skin toxicities in these cancer patients and the response to oncological treatment, based on Response Evaluation Criteria In Solid Tumors (RECIST). According to literature data, the patients who developed grade 3 or 4 CTCAE skin adverse reactions had a better outcome and cutaneous side effects seem to become a sign of drug activity and a marker of predictive response and survival to oncologic treatment [10, 11] . The results from our study were consistent with previously reported data, with response at 3 months signifycantly associated with the severity of skin toxicity.
Of course, our study has some limitations regarding the facts that it is a single center trial, with a relatively small number of patients. The cohort is heterogeneous, it includes patients that received both chemotherapy (taxanes) and targeted therapy (i.e. EGFR inhibitors).
Because of the limited number of patients included, we could not conduct extensive subgroup analysis; however we explored some potential confounders that might influence our results. The most important potential source of bias was the heterogeneity of treatment regimens, including both taxan-based and targeted therapy -our analysis showed there was no significant difference in the severity of cutaneous toxicity or the impact on patients's quality of life between these subgroups.
Because of the significant increase in the number of patients receiving cancer treatment with these new oncologic drugs, it is important to understand the impact of such adverse reactions on the patients' quality of life. The evaluation of the relationship between DLQI and dermatological toxicity caused by EGFR inhibitors was also recently analysed in the ObservEr study. This was an observational multicentric prospective trial that evaluated the efficacy of cetuximab (EGFRI) in first line treatment of stage IV colorectal patients, but it also studied the severity of skin reactions to this therapy and the impact of patients' quality of life, using the DLQI score. Good management of cutaneous adverse effects did not affect compliance to treatment, patients maintained a good QoL and the investigators observed a positive association between skin toxicity and response to treatment [12] , findings which are similar to those of our own study.
To our knowledge, ours is the first prospective study of oncologic patients with skin toxicities in Romania. Our findings are generally consistent with data previously cited in the literature, with a novel element related to the potential relationship between patient gender and perceived deterioration of QOL. Further studies are required to investigate this particular relationship and potential causal mechanisms in order to better understand and manage the side effects of cancer therapy. 
